Table 2

Estimates of concordance of serum values with clinical status of patients treated with trastuzumab

Concordance

HER2/neu

CA15-3

Series test^a

C^b

0.793

0.627

0.829

^aChange was considered positive if it was ≥ 15% for HER2/neu and ≥ 21% for CA15-3. ^bDifferences in concordance for HER2/neu and CA15-3 with 95%CI = 0.166 (lower limit 0.102, upper limit 0.227).

Esteva et al. Breast Cancer Research 2005 7:R436   doi:10.1186/bcr1020